Through engagement in a series of collaborations and international consortia, his current biomedical proteomics research is directed to the discovery and development of protein biomarkers. On-going projects are focussed on the mass spectrometry based measurement and evaluation of protein biomarkers in oncology and inflammatory disease to progress them to clinical utility. Steve's team are also investigating the mechanisms of disease progression focussing on prostate cancer and psoriatic arthritis.
Steve is highly energetic and enthusiastic with an innovative, open and inclusive approach to his work. He has given over 200 invited presentations at international events, published over 80 scientific papers, edited and contributed to several books including editing one of the first books on Proteomics that was translated into Chinese and Japanese. Steve has held roles as a committee member in the British Society for Proteome Research (currently vice-President, and the European Proteomics Association. He is the lead organiser of the forthcoming annual world congress of the Human Proteome Organisation (HUPO) that will be held in the national Convention Centre in Dublin from 17-21st September 2017 (www.hupo2017.ie).
Recently, Steve founded the UCD spinout company 'Atturos' (Dec 2016) to support the delivery of OCProDx to clinical use. OCProDx is a prostate cancer blood-based biomarker test that has the capability to distinguish patients with organ-confined and non-organ confined disease. The test will help inform men diagnosed with prostate cancer whether they should go on or stay on 'active surveillance' The Atturos team has the expertise and experience to deliver this and other multiplexed protein biomarker tests to market.